Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HEXO NASDAQ:IRWD NASDAQ:MCRB NASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsIRWDIronwood Pharmaceuticals$0.77+1.0%$0.72$0.53▼$6.57$123.63M0.331.20 million shs1.11 million shsMCRBSeres Therapeutics$13.99-1.9%$10.33$6.53▼$26.40$124.52M2.89147,021 shs47,064 shsSEERSeer$2.13+0.5%$2.12$1.59▼$2.63$124.80M1.5787,860 shs107,673 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEXOHEXO0.00%0.00%0.00%0.00%0.00%IRWDIronwood Pharmaceuticals+0.97%-5.50%+4.29%-17.26%-88.71%MCRBSeres Therapeutics-1.89%-3.72%+28.82%+45.28%-47.80%SEERSeer+0.47%-3.18%-3.62%+3.90%+7.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/AIRWDIronwood Pharmaceuticals4.4312 of 5 stars3.15.00.03.43.20.81.9MCRBSeres Therapeutics2.9283 of 5 stars2.91.00.04.61.70.80.0SEERSeer1.9866 of 5 stars3.01.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEXOHEXO 0.00N/AN/AN/AIRWDIronwood Pharmaceuticals 2.13Hold$4.78520.08% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67426.57% UpsideSEERSeer 2.00Hold$3.0040.85% UpsideCurrent Analyst Ratings BreakdownLatest HEXO, SEER, IRWD, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29IRWDIronwood Pharmaceuticals$351.41M0.36$0.05 per share15.45($1.88) per share-0.41MCRBSeres Therapeutics$126.32M0.97N/AN/A$1.61 per share8.69SEERSeer$14.17M8.85N/AN/A$5.54 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/AIRWDIronwood Pharmaceuticals$880K-$0.20N/A3.09N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/6/2025 (Estimated)SEERSeer-$86.60M-$1.41N/AN/AN/A-560.90%-24.69%-22.13%8/6/2025 (Estimated)Latest HEXO, SEER, IRWD, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02N/AN/AN/AN/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A8/6/2025Q2 2025SEERSeer-$0.39N/AN/AN/A$3.75 millionN/A5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEXOHEXON/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEXOHEXO0.010.410.24IRWDIronwood PharmaceuticalsN/A3.343.34MCRBSeres TherapeuticsN/A2.112.11SEERSeerN/A19.3418.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEXOHEXO7.78%IRWDIronwood PharmaceuticalsN/AMCRBSeres Therapeutics59.34%SEERSeer75.20%Insider OwnershipCompanyInsider OwnershipHEXOHEXO4.69%IRWDIronwood Pharmaceuticals12.70%MCRBSeres Therapeutics4.70%SEERSeer11.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEXOHEXO1,27744.00 million41.93 millionOptionableIRWDIronwood Pharmaceuticals220161.82 million141.27 millionOptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableSEERSeer16058.87 million52.23 millionOptionableHEXO, SEER, IRWD, and MCRB HeadlinesRecent News About These CompaniesUAE: Al Seer Marine’s fleet expansion drives 20% higher revenues in H1-25August 1 at 2:16 AM | zawya.comZProphet One God shares doom prophecy about Lil Win, video stirs controversyJuly 31 at 4:14 PM | msn.comSeer to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 31 at 4:05 PM | globenewswire.comSeer (SEER) Expected to Announce Quarterly Earnings on WednesdayJuly 31 at 10:49 AM | marketbeat.comSeer Faces Nasdaq Compliance Challenge After Annual MeetingJuly 31 at 2:36 AM | theglobeandmail.comLufthansa, Fraport, and zeroG drive innovation at Frankfurt AirportJuly 30 at 10:55 AM | breakingtravelnews.comBAl Seer Marine reports AED698 million in revenue for H1 2025July 30 at 10:55 AM | msn.comSeer (NASDAQ:SEER) Stock Price Down 0.9% - Should You Sell?July 30 at 2:59 AM | americanbankingnews.comSeer (NASDAQ:SEER) Trading Down 0.9% - Time to Sell?July 30 at 2:57 AM | marketbeat.comSeer Green man says having Birmingham NHS surgery saved jobJuly 29, 2025 | msn.comAl Seer Marine reports increase in operating profit to AED 156mlnJuly 29, 2025 | zawya.comZWhen all are treated equally, conflicts end, peace prevails, says Dingaleshwar SwamiJuly 28, 2025 | thehindu.com2023 election seer returns with 2027 forecast, predicts outcome of electionJuly 26, 2025 | msn.comLufthansa, Fraport partner on AI tech for aircraft handling at Frankfurt AirportJuly 25, 2025 | airport-technology.comALufthansa, Fraport, Zerog Drive Innovation At FRAJuly 25, 2025 | airwaysmag.comALufthansa, Fraport, and zeroG Introduce AI-Based Camera 'Seer' at Frankfurt AirportJuly 25, 2025 | aviationpros.comASeer to Report Second Quarter 2025 Financial Results on August 6, 2025July 22, 2025 | globenewswire.comSadhguru visits Suttur Mutt to thank seerJuly 21, 2025 | timesofindia.indiatimes.comPanchamasali seer hospitalised after food poisoningJuly 19, 2025 | timesofindia.indiatimes.comPanchamasali Trust mulls alternative to seer in KudalasangamaJuly 19, 2025 | timesofindia.indiatimes.comPanchamasali rift: Trust decides to choose a new seerJuly 19, 2025 | thehindu.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEXO, SEER, IRWD, and MCRB Company DescriptionsHEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.Ironwood Pharmaceuticals NASDAQ:IRWD$0.77 +0.01 (+0.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.78 +0.00 (+0.47%) As of 08/1/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Seres Therapeutics NASDAQ:MCRB$13.99 -0.27 (-1.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.95 -0.04 (-0.29%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Seer NASDAQ:SEER$2.13 +0.01 (+0.47%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.13 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
